Home » Stocks » Fluidigm

Fluidigm Corporation (FLDM)

Stock Price: $6.45 USD -0.26 (-3.87%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $6.46 +0.01 (0.16%) Oct 23, 7:18 PM

Stock Price Chart

Key Info

Market Cap 459.99M
Revenue (ttm) 112.61M
Net Income (ttm) -54.57M
Shares Out 71.32M
EPS (ttm) -0.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $6.45
Previous Close $6.71
Change ($) -0.26
Change (%) -3.87%
Day's Open 6.73
Day's Range 6.36 - 6.81
Day's Volume 1,832,498
52-Week Range 1.17 - 12.45

More Stats

Market Cap 459.99M
Enterprise Value 509.92M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 71.32M
Float 70.20M
EPS (basic) -0.78
EPS (diluted) -0.78
FCF / Share -0.29
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 8.26M
Short Ratio 1.91
Short % of Float 11.77%
Beta 2.05
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.08
PB Ratio 3.73
Revenue 112.61M
Operating Income -51.67M
Net Income -54.57M
Free Cash Flow -20.67M
Net Cash -49.93M
Net Cash / Share -0.70
Gross Margin 57.08%
Operating Margin -45.88%
Profit Margin -48.50%
FCF Margin -18.35%
ROA -11.12%
ROE -35.74%
ROIC -40.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$14.00*
(117.05% upside)
Low
12.0
Current: $6.45
High
16.0
Target: 14.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue11711310210411511671.1852.3342.8733.56
Revenue Growth3.79%10.82%-2.4%-8.95%-1.5%63.6%36.02%22.09%27.73%-
Gross Profit64.2861.6551.9858.4468.0873.6150.9837.0129.6721.98
Operating Income-51.84-48.16-58.36-73.19-50.16-51.84-18.65-18.07-18.57-14.57
Net Income-64.79-59.01-60.54-75.99-53.32-52.83-16.53-19.02-22.47-16.90
Shares Outstanding66.7839.6532.9829.0128.7127.7725.4822.1417.851.89
Earnings Per Share-0.97-1.49-1.84-2.62-1.86-1.90-0.65-0.86-1.81-8.94
Operating Cash Flow-35.21-25.20-24.10-39.14-34.73-22.62-1.59-17.48-17.54-11.51
Capital Expenditures-2.53-0.37-1.57-5.07-3.98-7.40-3.45-2.38-1.68-1.53
Free Cash Flow-37.74-25.57-25.66-44.20-38.72-30.03-5.04-19.86-19.22-13.04
Cash & Equivalents58.6495.4063.1459.4394.9711584.3480.0153.475.72
Total Debt59.98172195195195195--10.1417.83
Net Cash / Debt-1.34-76.66-132-136-99.70-80.1584.3480.0143.33-12.10
Assets26530428730637040811711479.3324.80
Liabilities11123225625325525720.5013.0822.4329.42
Book Value15472.1230.9453.2311515096.4110156.90-189
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Fluidigm Corporation
Country United States
Employees 566
CEO Stephen Christopher Linthwaite

Stock Information

Ticker Symbol FLDM
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: FLDM
IPO Date February 10, 2011

Description

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments, consumables, and services to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. Fluidigm Corporation sells its products to academic institutions, life sciences, and clinical research laboratories that conduct research, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.